Hong Kong
Asset 2brandhk en scaled 2


Dear Friends of HKBIO and Biotechnology Peers,

On behalf of the Hong Kong Biotechnology Organization (HKBIO), we would like to cordially invite you to the first international biotech conference, BIOHK2020 in Hong Kong.

Biotechnology has emerged as one of the fastest growing sectors in Hong Kong and China in recent years. Recognizing its potential, the government has offered strong support through investment towards research and development and the building of infrastructure to foster close connections between industry, academia and investors. According to the Research Grants Council, between 2013/14 and 2017/18, 803 biotechnology-related projects in local universities were publicly-funded amounting to HK$1.2 billion, while outside of academia, through the Innovation and Technology Fund, over 460 biotechnology projects have been funded including those related to non-invasive prenatal diagnosis, robotics-assisted minimally invasive surgery and mini artificial heart.

Hong Kong, often considered the gateway to China due to its unique status as a special administrative region, offers a rich source of opportunities for overseas investors looking to capitalize the continued growth of the Greater Bay Area (GBA) – a scheme initiated by the Chinese government to link Hong Kong and 10 other cities along the Pearl River Estuary and form an international technology and innovation centre rivalling that of Silicon Valley. With its strong exposure and international integration, Hong Kong has become the go-to stepping stone for Chinese companies looking to expand abroad. New listing rules adopted by the Hong Kong Stock Exchange (HKEX) allows pre-revenue biotech companies to be listed on the exchange. A first in Asia, it ensures that more capital can flow freely towards a sector that has been largely deprived in the region until recently. As of May 1, 2019, of the 7 biotech companies that completed their IPOs since the new listing rule, almost half have experienced a share price increase upwards of 65% from its issuance price. As such, owing to its geopolitical advantage, large number of world class universities and its position as the No. 1 biotech IPO market in Asia, Hong Kong has the potential to be at the epicentre of Asia’s biotech revolution and it is our hope that BIOHK2020 will help set this in motion.

As a city with a rich history in industrial development and innovation, and one that is frequently coined “Asia’s World City”, there is no better place to bring biotech companies from East and West together other than here at BIOHK2020. The first of its kind in Hong Kong, the conference represents a new chapter both for the local biotech industry and the city itself as it is often when deals are first announced and when peers within the industry seek strategic collaborations. Take charge and seize the many opportunities available and engage with global industry leaders at BIOHK2020.

Despite the recent challenges Hong Kong has been facing, biotech innovation and development should not come to a halt. As the situation in Hong Kong is improving, we are instead motivated to continue to inspire and educate our community, building a more advanced biotech future across all industries. We are certain that Hong Kong’s future remains bright as ever as biotechnology continues to be the pillar of Hong Kong’s technological development plans.

Register now to save more money. Our team is always there to help you and look forward to seeing you in Aug 2020. 

Yours sincerely,

avatar 61
Professor Albert Cheung-hoi YU, PhD, JP
President, BIOHK2020
Chairman, Hong Kong Biotechnology Organization (HKBIO)
Chairman, Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance
Professor, Peking University